Finance

Lists
Why is AKBA up ५.२६%?
Dive Deeper
AKBA:NASDAQ
Akebia Therapeutics Inc
US$ ०.९१
+५.२६%
(+०.०४५) 1D
US$ ०.९०
-१.१५% (-०.०११)
After hours
Closed: अक्टोबर ५, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKBA...
Open
US$ ०.८७
High
US$ ०.९२
Low
US$ ०.८५
Mkt. cap
२५.०९ करोड
Avg. vol.
७८.६५ लाख
Volume
७५.०५ लाख
52-wk high
US$ ३.१८
52-wk low
US$ ०.८१
EPS
-US$ ०.११
Beta
०.१८
Shares outstanding
२७.७१ करोड
No. of employees
१९४
Open
US$ ०.८७
High
US$ ०.९२
Low
US$ ०.८५
Mkt. cap
२५.०९ करोड
Avg. vol.
७८.६५ लाख
Volume
७५.०५ लाख
52-wk high
US$ ३.१८
52-wk low
US$ ०.८१
EPS
-US$ ०.११
Beta
०.१८
Shares outstanding
२७.७१ करोड
No. of employees
१९४
News stories
From web sources and news partners
Stock Titan
Stock Titan
·
३५ मिनेट पहिले
Why Small Caps Are Lagging the Nasdaq Record in 2026
Yahoo Finance
Yahoo Finance
·
६ घण्टा पहिले
Is the economy awful? S&P 500 and job market say otherwise
Reuters
Reuters
·
१ घण्टा पहिले
COMMENTARY: TRADING DAY Nasdaq highs, Brazil surprise
About Akebia Therapeutics Inc
CEO-
Employees१९४
Founded२००७ जनवरी १
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websiteakebia.com
Analyst ratings
Based on 5 analysts giving stock ratings to AKBA in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for AKBA in the last 3 months.
Highest
Current US$ ०.९१
US$ ६.०० (+५५८.९८%)
Average
US$ ३.९० (+३२८.३४%)
Lowest
US$ १.०० (+९.८३%)
Analyst
Recommendation
Action
Price target
Projected
Date
Julian Harrison
BTIG
Buy
Maintained
US$ ४.००
+३३९.३%
09/14/2026
Ed Arce
Westpark Capital
Buy
Initiated
US$ ४.५०
+३९४.२%
09/08/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
US$ ४.००
+३३९.३%
08/17/2026
Roanna Ruiz
Leerink Partners
Hold
Downgraded
US$ १.००
+९.८%
08/07/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
US$ ६.००
+५५९%
08/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
५.८८ करोड
५.७६ करोड
५.३५ करोड
४.९१ करोड
Cost of goods sold
१.०३ करोड
१.०९ करोड
९७.८१ लाख
९५.७९ लाख
Cost of revenue
१.०३ करोड
१.०९ करोड
९७.८१ लाख
९५.७९ लाख
Research and development expenses
१.४९ करोड
२.६६ करोड
१.४८ करोड
१.४१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.९१ करोड
२.६१ करोड
३.०४ करोड
२.८२ करोड
Operating expense
४.४० करोड
५.२७ करोड
४.५२ करोड
४.२२ करोड
Total operating expenses
५.४३ करोड
६.३७ करोड
५.५० करोड
५.१८ करोड
Operating income
४४.४९ लाख
-६०.४८ लाख
-१४.८० लाख
-२६.८१ लाख
Other non operating income
१४.५४ लाख
२१.४५ लाख
४.५९ लाख
५.५९ लाख
EBT including unusual items
११.५५ लाख
-१.१२ करोड
-८९.२८ लाख
-८८.३८ लाख
EBT excluding unusual items
११.५५ लाख
-८७.३० लाख
-५७.१२ लाख
-५१.९३ लाख
Income tax expense
६.१५ लाख
१०.०९ लाख
१.२६ लाख
७०.०० हजार
Effective tax rate
५३.२५%
-८.९८%
-१.४१%
-०.७९%
Other operating expenses
-
-
-
-
Net income
५.४० लाख
-१.२२ करोड
-९०.५४ लाख
-८९.०८ लाख
Net profit margin
०.९२%
-२१.२५%
-१६.९१%
-१८.१३%
Earnings per share
-
-०.०५
-०.०३
-०.०३
Interest and investment income
-
-
-
-
Interest expense
-४७.४८ लाख
-४८.२७ लाख
-४६.९१ लाख
-३०.७१ लाख
Net interest expenses
-४७.४८ लाख
-४८.२७ लाख
-४६.९१ लाख
-३०.७१ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
४७.६७ लाख
-५७.२७ लाख
-११.५२ लाख
-२०.९६ लाख
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू